Compared to Estimates, Idex (IEX) Q4 Earnings: A Look at Key Metrics

Idex (IEX) reported $862.9 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 9.4%. EPS of $2.04 for the same period compares to $1.83 a year ago.The reported revenue represents a surprise of -0.24% over the Zacks Consensus Estimate of $864.97 million. With the consensus EPS estimate being $2.03, the EPS surprise was +0.49%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Idex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales - Organic impact - YoY change: 3% versus the two-analyst average estimate of 3.7%. Net Sales- Fluid & Metering Technologies (FMT): $299.30 million compared to the $315.03 million average estimate based on three analysts. The reported number represents a change of +0.1% year over year. Intersegment sales eliminations: -$2.50 million compared to the -$0.98 million average estimate based on three analysts. Net Sales- Fire & Safety/Diversified Products (FSDP): $192.90 million compared to the $190.13 million average estimate based on three analysts. The reported number represents a change of +7.8% year over year. Net Sales- Health & Science Technologies (HST): $373.20 million versus $360.84 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change. Adjusted EBITDA- Fluid & Metering Technologies (FMT): $94.70 million compared to the $101 million average estimate based on two analysts. Adjusted EBITDA- Corporate: -$20.10 million versus the two-analyst average estimate of -$21.95 million. Adjusted EBITDA- Fire & Safety/Diversified Products (FSDP): $54.30 million versus the two-analyst average estimate of $53.40 million. Adjusted EBITDA- Health & Science Technologies (HST): $98.60 million versus the two-analyst average estimate of $101.95 million. View all Key Company Metrics for Idex here>>>Shares of Idex have returned +4.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEX Corporation (IEX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks